N-(1-benzylpiperidin-4-yl)propylamine | 160358-05-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(1-benzylpiperidin-4-yl)propylamine
• 英文别名: 1-benzyl-4-propylaminopiperidine；1-benzyl-N-propylpiperidin-4-amine
• CAS: 160358-05-4
• 化学式: C₁₅H₂₄N₂
• mdl: MFCD09860638
• 分子量: 232.369
• InChiKey: ZSFAYUNTAZFHHB-UHFFFAOYSA-N

物化性质

• 沸点：
  325.6±35.0 °C(Predicted)
• 密度：
  0.99±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(1-benzylpiperidin-4-yl)propylamine 在 盐酸 、 titanium(III) chloride 作用下， 反应 20.08h， 生成 1-benzyl-4-[N-propyl-N-(3-amino-2-pyridinyl)amino]piperidine
  参考文献：
  名称：

  Targeting Delavirdine/Atevirdine Resistant HIV-1:  Identification of (Alkylamino)piperidine-Containing Bis(heteroaryl)piperazines as Broad Spectrum HIV-1 Reverse Transcriptase Inhibitors

  摘要：

  A novel class of bis(heteroaryl)piperazine (BHAP) analogs which possesses the ability to inhibit NNRTI (non-nucleoside reverse transcriptase inhibitor) resistant recombinant HIV-1 reverse transcriptase (RT) and NNRTI resistant variants of HIV-1 has been identified via targeted screening. Further investigation of the structure-activity relationships of close congeners of these novel (alkylamino)piperidine BHAPs (AAP-BHPSs) led to the synthesis of several compounds possessing the desired phenotype (e.g., activity against recombinant RTs carrying the Y181C and P236L substitutions). Further structural modifications were required to inhibit metabolism and modulate solubility in order to obtain compounds with the desired biological profile as well as appropriate pharmaceutical properties. The AAP-BHAPs with the most suitable characteristics were compounds 7, 15, and 36.

  DOI：

  10.1021/jm960158n
• 作为产物：
  描述：

  N-苄基哌啶酮 在 甲酸 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 52.0h， 生成 N-(1-benzylpiperidin-4-yl)propylamine
  参考文献：
  名称：

  具有抗HIV活性的3-氨基丙酸哌啶酰胺类化 合物，合成方法及用途

  摘要：

  本发明涉及式I所示的3‑氨基丙酸哌啶酰胺类化合物及其药学上可接受的盐或溶剂合物，其中各个取代基的定义同权利要求，所述化合物的制备方法，含有它们的药物组合物及其在制备用于治疗与HIV感染有关的疾病和病症的药物中的用途。

  公开号：

  CN103130709B

文献信息

• Alkyl substituted piperadinyl and piperazinyl anti-AIDS compounds
  申请人：Pharmacia & Upjohn Company

  公开号：US05866589A1

  公开（公告）日：1999-02-02

  Anti-AIDS compounds of formula (I) ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, and R.sub.7 are as defined in the specification and R.sub.8 is alkyl of substituted alkyl.

  化合物的抗艾滋病公式（I）##STR1##其中R.sub.1、R.sub.2、R.sub.3、R.sub.4、R.sub.5、R.sub.6和R.sub.7如规范中定义，R.sub.8是取代烷基的烷基。
• [EN] ALKYL SUBSTITUTED PIPERADINYL AND PIPERAZINYL ANTI-AIDS COMPOUNDS<br/>[FR] COMPOSES DE PIPERADINYLE ET PIPERAZINYLE ANTI-SIDA A SUBSTITUTION ALKYLE
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：WO1996018628A1

  公开（公告）日：1996-06-20

  (EN) Anti-AIDS compounds of formula (I), where the aromatic/heteroaromatic ring is bonded to a carbon atom of the R8 substituent are disclosed as well as specific Anti-AIDS pyridines (V).(FR) L'invention se rapporte à des composés anti-SIDA de la formule (I) dans laquelle le noyau aromatique/hétéroaromatique est lié à un atome de carbone du substituant de R8, ainsi qu'à des pyridines (V) spécifiques anti-SIDA.

  抗艾滋病化合物的公式（I）被揭示，其中芳香/杂环芳香环与R8取代基的一个碳原子结合，以及特定的抗艾滋病吡啶（V）。
• HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE
  申请人：Itai Akiko

  公开号：US20100234363A1

  公开（公告）日：2010-09-16

  Disclosed is a compound which is useful as an 11β-hydroxysteroid dehydrogenase type 1 inhibitor. A compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof, wherein X is O or S, a broken line and a wavy line represent the presence or the absence of a bond, (i) when a broken line represents the presence of a bond, a wavy line represents the absence of a bond, R 2 and R 3 are each independently hydrogen, halogen, cyano, hydroxy, carboxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or the like, (ii) when a broken line represents the absence of a bond, a wavy line represents the presence of a bond, R 1 and R 4 are each independently hydrogen, halogen or the like, R 2 and R 3 are each independently hydrogen, halogen, cyano, hydroxy, carboxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or the like, and R 5 and R 6 are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or the like.

  本发明涉及一种化合物，可用作11β-羟基类固醇脱氢酶1型抑制剂。化合物的表示式如下：其药学上可接受的盐或其溶剂化物，其中X为O或S，一条断线和一条波浪线分别表示键的存在或不存在，(i) 当断线表示键的存在时，波浪线表示键的不存在，R2和R3各自独立地表示氢、卤素、氰基、羟基、羧基、可选取代的烷基、可选取代的烯基、可选取代的炔基或类似物，(ii) 当断线表示键的不存在时，波浪线表示键的存在，R1和R4各自独立地表示氢、卤素或类似物，R2和R3各自独立地表示氢、卤素、氰基、羟基、羧基、可选取代的烷基、可选取代的烯基、可选取代的炔基或类似物，而R5和R6各自独立地表示氢、可选取代的烷基、可选取代的烯基、可选取代的炔基或类似物。
• Urea derivatives and their use as acat inhibitors
  申请人：NISSHIN FLOUR MILLING CO., LTD.

  公开号：EP0625507A2

  公开（公告）日：1994-11-23

  Urea derivatives of formula (I) wherein the valuable groups are as defined in the specification, which possess both an ACAT inhibitory activity and an antioxidative activity. Those derivatives are useful in the prophylaxis and treatment of hypercholesterolemia and atherosclerosis.

  式 (I) 的脲衍生物 其中有价基团如说明书中所定义，具有 ACAT 抑制活性和抗氧化活性。这些衍生物可用于预防和治疗高胆固醇血症和动脉粥样硬化。
• Synthesis and Structure−Activity Relationships of the (Alkylamino)piperidine-Containing BHAP Class of Non-Nucleoside Reverse Transcriptase Inhibitors:  Effect of 3-Alkylpyridine Ring Substitution
  作者：Michael J. Genin、Toni J. Poel、Paul D. May、Laurice A. Kopta、Yoshihiko Yagi、Robert A. Olmsted、Janice M. Friis、Richard L. Voorman、Wade J. Adams、Richard C. Thomas、Donna L. Romero

  DOI：10.1021/jm990051a

  日期：1999.10.1

  Development of resistance to currently approved HIV therapies has continued to fuel research efforts to improve the metabolic stability and spectrum of activity of the (alkyl amino)piperidine containing bis(heteroaryl)piperazine (AAP-BHAP) class of non-nucleoside reverse transcriptase inhibitors (NNRTIs). The synthesis of analogues in which the usual 3-alkylamino substituent on the pyridine ring is replaced by a 3-alkyl substituent led to compounds which retained activity against recombinant P236L and wild-type (WT) reverse transcriptase (RT), while inhibition of the Y181C mutant RT was reduced relative to the activity of the 3-alkylamino-substituted congeners. Testing of representative analogues in an in vitro liver microsome assay indicated that the alkyl substituent would not appreciably improve the metabolic stability of the AAP-BHAP template. In vivo pharmacokinetic evaluation of three compounds confirmed these results in that high systemic clearances were observed. Nevertheless, one compound (13), PNU-103657, possessed oral bioavailability in rats approaching that of the structurally related NNRTI drug delavirdine which is currently on the market for the treatment of HIV infection.